The NATURE - Scientific Reports® - for the first time publishes the results of the of research conducted in Poland on Artificial Medical Intelligence conducted by a team of scientists from the listed -- MEDICA - World Forum for Medicine

08/08/2022

Milton Essex S. A.

The NATURE - Scientific Reports® - for the first time publishes the results of the of research conducted in Poland on Artificial Medical Intelligence conducted by a team of scientists from the listed

Medical-technology company MILTON ESSEX SA (listed on the NewConnect market since 2021) is the co-funding leader of the research program, part of a broader project on the use of Artificial Intelligence for the automated processing of medical imaging data - the first time in the history of The NATURE Scientific Reports® prestigious scientific journal - the results of research in this highly competitive field initiated and led by a Polish private company in collaboration with with renowned academic centers, have found recognition in the eyes of international reviewers and have been recognized as world-class results.
Artificial Intelligence is currently one of the fastest growing areas of research and the greater is the success of the Polish multidisciplinary team of scientists consisting of engineers led by by Prof. Robert Nowak of the Institute of Computer Science at the Warsaw University of Technology and from specialists in multispectral medical imaging and physicians led by Prof. Jacek Stępień of Milton Essex SA and Prof. Karina Jahnz-Różyk of the Military Medical Institute.

The results, published in The NATURE Scientific Reports®, concern a novel solution for multispectral medical imaging using the far-infrared spectrum (LWIR).
The solution represents a true breakthrough in automated digital analysis of skin tissue pathology of skin tissue, making it possible to detect subminimal lesions less than 0.3 mm in diameter, allowing for the precise identification of a new type of functional cutaneous allergic reaction markers (HARM - Hyperthermic Allergic Reaction Markers). In the completed IRFAN (InfraRed Imaging of Field of Allergic Reaction MESX/ISC/09/18) clinical trials conducted at the Department of Internal Medicine, Pneumonology, Allergology and Clinical Immunology of the Military Medical Institute, a database of more than 1,500 images of cutaneous allergic reactions was accumulated, allowing for the successful validation of the Artificial Intelligence system.

SkinLogic™.
The developed novel model of medical SkinLogic™ Artificial Intelligence using coupled deep learning algorithms and a hybrid model with a key module in the form of a convolutional neural network neural network has achieved spectacular results in detecting allergic reactions compared to the clinical gold standard - achieving AUC (0.98) and AP (0.97) rates - which are accepted measures of the quality of medical tests. The quality of our AI's performance as determined by these indicators places it in the world's top league. It should be noted that the success achieved is all the greater because the development version of the system in the form of the SkinSens™ scanner (which is the result of work conducted jointly by Milton Essex SA and the Military Academy of Technology as part of the R&D consortium "FOTONICA"). ), has already had its European premiere in November 2021 at the largest industry international trade fair MEDICA'21 in Düsseldorf, where it received a great deal of interest from the medical community and medical technology specialists.  The system is currently undergoing the final pre-marketing tests necessary to bring it to market, and is poised for a program of testing pilot study aimed at early detection of inhalant allergies as key predictors of allergic asthma. The IRFAN-Allergoscope™ project is the world's first example of the successful and complete integration of medical non-invasive imaging equipment with advanced Artificial Intelligence algorithms to automatically read the test results. This opens a new chapter in the development of intelligent systems for rapid screening tests in critical areas of civilization diseases, which include allergies with a particular focusing on allergic asthma. According to the WHO, asthma already affects approx. 262 million people and has caused 461,000 deaths worldwide (2019). At that
it is estimated that the prevalence of asthma is already increasing by up to 50% every decade, and the disease itself is under-diagnosed and under-treated.
One of the main reasons for the development of asthma, unfortunately, is the allergic background caused by exposure to various environmental allergens present in the air.
Today, in many cases, it is possible to interrupt the allergic march leading to the development of asthma through the use of modern immunotherapy desensitization, but for this a precise and objective diagnosis identifying potential sources of sensitization by means of allergy testing is required.
The gold standard in this area is still skin testing, which in the 21st century needs strong support from the latest technologies both in terms of in terms of automating the recording of the tests themselves and their further interpretation by Artificial Intelligence. The system is currently undergoing the final pre-marketing tests necessary to bring it to market, and is poised for a program of studies pilot study aimed at early detection of inhalant allergies as key predictors of allergic asthma. The IRFAN-Allergoscope™ project is the world's first example of the successful and complete integration of medical non-invasive imaging equipment with advanced Artificial Intelligence algorithms to automatically read the test results. This opens a new chapter in the development of intelligent systems for rapid screening tests in critical areas of civilization diseases, which include allergies with a particular focusing on allergic asthma.

According to the WHO, asthma already affects approx. 262 million people and has caused 461,000 deaths worldwide (2019). At that it is estimated that the prevalence of asthma is already increasing by up to 50% every decade, and the disease itself is under-diagnosed and under-treated. One of the main reasons for the development of asthma, unfortunately, is the allergic background caused by exposure to various environmental allergens present in the air. Today, in many cases, it is possible to interrupt the allergic march leading to the development of asthma through the use of modern immunotherapy desensitization, but for this a precise and objective diagnosis identifying potential sources of sensitization by means of allergy testing is required.
The gold standard in this area is still skin testing, which in the 21st century needs strong support from the latest technologies both in terms of in terms of automating the recording of the tests themselves and their further interpretation by Artificial Intelligence.
Experts at MILTON ESSEX SA estimate that the use of the new SkinSens™ scanner equipped with the SkinLogic™ Artificial Intelligence system will translate into a a more than 10-fold acceleration of the entire allergy diagnosis procedure with identification of its causes, which in turn will open up millions of patients, especially children, broad access to early and effective treatment with desensitizing immunotherapies.

International consulting firm MarketSands forecasts that the global medical artificial intelligence (AI) market will grow from $6.9 billion in 2021 to around $67.4 billion by 2027, with the market growing at a CAGR of at least 46.2%. The key factors driving the growth of of this market are related to the ever-increasing need to reduce costs in both primary and specialty healthcare through, among other things, the automation of procedures and further shifting the burden of diagnostics to the family medicine level through the progressive integration of diagnostic functions with AI systems.
The excellent results obtained by the SkinLogic™ AI created by scientists from MILTON ESSEX SA and the Warsaw University of Technology in evaluating allergy tests allergic tests are fully in line with the global trend of AI development and provide a clear market perspective for the developed diagnostic system, the especially since it strongly supports the activities of global pharmaceutical companies aimed at accelerating instrumental diagnostics of allergy and increasing access, thanks to this, to the advanced desensitizing immunotherapies offered as well as to the modern treatment of allergic asthma.

The NATURE Scientific Reports® is the sixth most cited journal in the world, with more than 540,000 citations in 2020. (per Journ. Citation Reports® Science Edition, Clarivate Analytics, 2021). The journal has more than 2.4 million monthly readers and is indexed by: Web of
Science, PubMed, PubMed Central, Scopus, Dimensions, Google Scholar, DOAJ and SAO/NASA ADS.
The NATURE Scienfic Reports® metrics:
2-year impact-factor: 4,380
5-year impact-factor: 5,134
Immediacy Index: 0.783
Eigenfactor® Score: 1.23250
Article influence score: 1.285

As Iwona Kaczynska - President of MILTON ESSEX SA - points out, the published research results have already been translated into specific product solutions, and the ongoing ongoing work on a new system for automated in vivo allergy diagnostics has entered the final stage of preparation for registration in accordance with the requirements of the of the current European Medical Device Regulation 2017/745 (MDR). As part of this research, the company plans to expand the accumulated imaging database, which should provide an adequate test set for future validation in other markets as well.

Project Scientific Manager: Prof. Jacek Stępień tel. +48 510 738 710; e-mail: j.stepien@miltonessex.eu

We encourage you to read the article:




Exhibitor Data Sheet